Nicholas von Guionneau

Nicholas von Guionneau is a Principal at Catalio Capital Management based in London, UK, where he focuses on structured debt financing for commercial-stage healthcare innovators. He recently facilitated Catalio's $20 million credit investment in Amalgam Rx, subsequently joining the digital health technology company's board of directors as an observer. Additionally, he serves on the boards of several emerging biotechnology companies, including Character Biosciences, LifeSprout Bio, Proto Axiom, and SetPoint Medical. Before transitioning to venture capital, he worked as a clinical doctor at Guy’s and St. Thomas’ NHS Trust and completed a specialized postdoctoral fellowship at Johns Hopkins Medicine. He holds an MBBS and a BSc in Medical Sciences from Imperial College London. His current investment focus leverages his clinical expertise in neurotherapeutics, peripheral nerve regeneration, and implantable neurodevices to evaluate complex life sciences opportunities.